FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2266083835> ?p ?o ?g. }

• W2266083835 endingPage "111" @default.
• W2266083835 startingPage "100" @default.
• W2266083835 abstract "In the concluding Discussion session, emphasis focussed on the potential for interfering selectively with cell membranes and cell signalling in tumour as against normal tissues. There could be no doubt that tremendous advances are being made in our understanding of the molecular changes associated with malignancy and that the information available for the rational design of inhibitors of particular signalling pathways is increasingly sophisticated. There was a consensus that we need more information on the qualitative and quantitative differences in the structure and function of membranes and the signalling machinery in various normal tissues as compared to their cancerous counterparts. Ideally we will develop drug against, for example, specific forms of, let us say, protein kinase C or tyrosine kinase which are found to be predominantly active in neoplastic cells. This may well prove possible, at least in some instances, in which case a safe therapeutic margin will be assured. But differences may in other situations turn out to be in the level of expression rather than purely qualitative in nature, and the scale of the disparate expression may not always be great. Even in such situations, adequate therapeutic selectivity may still be achieved. This may derive from a damping down of signalling in the hyperactive tumour. Although there are legitimate concerns regarding the possible toxic effects of administering signal-wrecking molecules in man, we should not be pessimistic as there are clear precedents elsewhere in medicine for drugs acting on membrane signals proving to be safe and effective against expectation informed by hindsight. There may also be concerns about new forms of drug resistance. But this will be so for any new agent or novel target. And with mechanism of action clearly to the fore we should be able to predict resistance pathways in advance and devise appropriate circumvention strategies or targeted second line therapies. There was a palpable buzz at the meeting that this is a valid, different and above all rational approach. Not only that, but the new therapeutic molecules which we discover will themselves prove to be valuable tools with which to probe further into the mechanisms of malignancy and signal transduction. We had expected to see a bewildering amount of new information from the basic sciences of molecularbiology and cell physiology, and we got it. But it was also impressive to witness the number of new compounds coming through which look like real drugs or at least exciting lead compounds. The membrane-active ether lipids are in clinical trial. Bryostatin 1 will shortly join them.(ABSTRACT TRUNCATED AT 400 WORDS)" @default.
• W2266083835 created "2016-06-24" @default.
• W2266083835 creator A5003965204 @default.
• W2266083835 date "1990-01-01" @default.
• W2266083835 modified "2023-10-09" @default.
• W2266083835 title "The Cell membrane and cell signals: New targets for novel anticancer drugs" @default.
• W2266083835 cites W1515479627 @default.
• W2266083835 cites W1656644300 @default.
• W2266083835 cites W1964613715 @default.
• W2266083835 cites W1971776926 @default.
• W2266083835 cites W1971936465 @default.
• W2266083835 cites W1982134056 @default.
• W2266083835 cites W1986383101 @default.
• W2266083835 cites W1990094951 @default.
• W2266083835 cites W1991781635 @default.
• W2266083835 cites W1992472345 @default.
• W2266083835 cites W1993282564 @default.
• W2266083835 cites W1994141611 @default.
• W2266083835 cites W1997093700 @default.
• W2266083835 cites W2003275504 @default.
• W2266083835 cites W2007319015 @default.
• W2266083835 cites W2007768242 @default.
• W2266083835 cites W2016568386 @default.
• W2266083835 cites W2017499074 @default.
• W2266083835 cites W2022711149 @default.
• W2266083835 cites W2027047605 @default.
• W2266083835 cites W2029531386 @default.
• W2266083835 cites W2033436103 @default.
• W2266083835 cites W2039094079 @default.
• W2266083835 cites W2047846174 @default.
• W2266083835 cites W2052043438 @default.
• W2266083835 cites W2060802834 @default.
• W2266083835 cites W2069263862 @default.
• W2266083835 cites W2071495883 @default.
• W2266083835 cites W2073478078 @default.
• W2266083835 cites W2077686814 @default.
• W2266083835 cites W2091169894 @default.
• W2266083835 cites W2096077209 @default.
• W2266083835 cites W2133362776 @default.
• W2266083835 cites W2149439788 @default.
• W2266083835 cites W2154207182 @default.
• W2266083835 cites W2215584599 @default.
• W2266083835 cites W2415425181 @default.
• W2266083835 cites W314156795 @default.
• W2266083835 doi "https://doi.org/10.1093/oxfordjournals.annonc.a057686" @default.
• W2266083835 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1706612" @default.
• W2266083835 hasPublicationYear "1990" @default.
• W2266083835 type Work @default.
• W2266083835 sameAs 2266083835 @default.
• W2266083835 citedByCount "26" @default.
• W2266083835 countsByYear W22660838352012 @default.
• W2266083835 crossrefType "journal-article" @default.
• W2266083835 hasAuthorship W2266083835A5003965204 @default.
• W2266083835 hasBestOaLocation W22660838351 @default.
• W2266083835 hasConcept C10347200 @default.
• W2266083835 hasConcept C15744967 @default.
• W2266083835 hasConcept C169760540 @default.
• W2266083835 hasConcept C180747234 @default.
• W2266083835 hasConcept C42362537 @default.
• W2266083835 hasConcept C60644358 @default.
• W2266083835 hasConcept C62478195 @default.
• W2266083835 hasConcept C70721500 @default.
• W2266083835 hasConcept C71924100 @default.
• W2266083835 hasConcept C86803240 @default.
• W2266083835 hasConcept C95444343 @default.
• W2266083835 hasConceptScore W2266083835C10347200 @default.
• W2266083835 hasConceptScore W2266083835C15744967 @default.
• W2266083835 hasConceptScore W2266083835C169760540 @default.
• W2266083835 hasConceptScore W2266083835C180747234 @default.
• W2266083835 hasConceptScore W2266083835C42362537 @default.
• W2266083835 hasConceptScore W2266083835C60644358 @default.
• W2266083835 hasConceptScore W2266083835C62478195 @default.
• W2266083835 hasConceptScore W2266083835C70721500 @default.
• W2266083835 hasConceptScore W2266083835C71924100 @default.
• W2266083835 hasConceptScore W2266083835C86803240 @default.
• W2266083835 hasConceptScore W2266083835C95444343 @default.
• W2266083835 hasIssue "2" @default.
• W2266083835 hasLocation W22660838351 @default.
• W2266083835 hasLocation W22660838352 @default.
• W2266083835 hasOpenAccess W2266083835 @default.
• W2266083835 hasPrimaryLocation W22660838351 @default.
• W2266083835 hasRelatedWork W1492315459 @default.
• W2266083835 hasRelatedWork W1512434910 @default.
• W2266083835 hasRelatedWork W2022803902 @default.
• W2266083835 hasRelatedWork W2139970489 @default.
• W2266083835 hasRelatedWork W2540910169 @default.
• W2266083835 hasRelatedWork W3089780453 @default.
• W2266083835 hasRelatedWork W3140454661 @default.
• W2266083835 hasRelatedWork W3148904318 @default.
• W2266083835 hasRelatedWork W3197854638 @default.
• W2266083835 hasRelatedWork W4245029315 @default.
• W2266083835 hasVolume "1" @default.
• W2266083835 isParatext "false" @default.
• W2266083835 isRetracted "false" @default.
• W2266083835 magId "2266083835" @default.
• W2266083835 workType "article" @default.